Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Organon Pays $103 Million to Acquire Global Rights for Two Henlius Biosimilars

publication date: Jun 13, 2022

Organon (NYSE: OGN), a New Jersey women’s health company, in-licensed global rights (ex-Greater China) for two biosimilars developed by Shanghai Henlius Biotech (HK; 2696) for $73 million upfront and $30 million in near-term milestones. Under the terms of the deal, Organon will market a biosimilar referencing Perjeta® for patients with HER2+ breast cancer and a biosimilar to Prolia®/Xgeva® for osteoporosis. Henlius will be in charge of regulatory matters and will supply the two drugs to Organon. In addition, Organon will have an option to negotiate rights to a Yervoy biosimilar. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here